Peripheral Vascular Disease (PVD) Diagnostics Market Size, Share, Growth, Trends, and Global Industry Analysis: By Type (Stents, Catheters, Endografts, Atherectomy Devices, Stent-Grafts) By Application (Coronary Artery Disease, Peripheral Arterial Disease, Venous Thromboembolism, Renal Artery Disease, Carotid Artery Disease) By Material (Metallic, Biodegradable, Polymer-based, Nitinol-based, Platinum-based) Modality (Invasive, Minimally invasive, Non-invasive) and Region Forecast 2020-2031

Peripheral Vascular Disease (PVD) Diagnostics Market size was valued at US$ x million in 2024 and is expected to reach US$ x million by 2031, growing at a significant CAGR of x% from 2025-2031. Moreover, the U.S. Global Peripheral Vascular Disease (PVD) Diagnostics Market is projected to grow significantly, reaching an estimated value of US$ XX Million by 2031. The market refers to the market that involves diagnostic technologies and equipment utilized in diagnose and assess peripheral vascular diseases, which compromise blood circulation outside the brain and heart.

The diagnostic market for peripheral vascular disease is driven by the rising prevalence of cardiovascular diseases, aging demographics, and greater awareness of early detection tests. Technological advancements in non-invasive imaging and diagnostic equipment and increased healthcare infrastructure further drive growth in the market. Government policies supporting early screening and preventive treatment also lead to higher adoption rates. Yet, the market is constrained by factors such as high diagnostic advanced equipment costs, limited availability in the developing world, and regulatory matters in terms of approval processes. Reimbursement constraints as well as the need for professional operators to manage diagnostic systems also represent barriers to widespread adoption that influence overall market growth.

Facts & Figures

• Peripheral Artery Disease (PAD), is estimated to affect around 7% of the adult population in the United States. This means that about 8.5 million adults in the U.S. are living with PVD. In the United States, in 2023, ~4.6 million males and ~5.2 million females were affected with Peripheral Artery Disease (PAD).
• Diabetic Patients: The prevalence of PVD is significantly higher in individuals with diabetes, with some studies reporting rates as high as 77%.
• Smoking is associated with the highest risk of PAD development with an odds ratio of 2.7 (95% CI 2.4–3.1). History of cardiovascular disease and diabetes are also significant risk factors with odds ratios of 2.6 (95% CI 2.2-3) and 1.9 (1.7-2.1), respectively.
• The disease is uncommon in younger populations; however, incidence increases sharply, with over 20% of people over 80 years old having PAD.

Key Developments:

• In June 2024, For those with venous blockages, Philips introduced its Duo Venous Stent System in the United States. With two different models to address various venous issues, this ground-breaking device, which received approval in December, aims to address the fundamental issues of chronic deep vein thrombosis.
• In April 2024, Abbott's ground-breaking Esprit BTK System, which makes use of an Enviroximes Eluting Resorbable Scaffold, was formally approved by the U.S. FDA. This innovative method is designed to treat chronic limb-threatening ischemia (CLTI) that affects the BTK.
• In January 2024, Cook Group launched its Slip-Cath Beacon Tip Hydrophilic Selective Catheter in the United States and Canada. Because it can be used for both vascular and nonvascular procedures, this catheter gives medical professionals flexibility.
• In June 2023, Cook Medical added new sizes and locations to its Advance Serenity hydrophilic PTA balloon catheter products. The device is commonly employed for above- & below-the-knee procedures on patients who suffer from Peripheral Artery Disease (PAD). The device is already available in the U.S. and Canada and recently extended. Additionally, it will become available in Europe in a few months from now.

Peripheral Vascular Disease (PVD) Diagnostics Market Segmentation:

Based on the type:

• Stents
• Catheters
• Endografts
• Atherectomy Devices
• Stent-Grafts

Stents will dominate the market, followed by their widespread application in peripheral artery disease and increasing cases of cardiovascular disease. Technological advancements, such as drug-eluting stents and bioresorbable stents, are enhancing treatment and fueling market growth. Growth in the elderly population, along with lifestyle factors for diabetes and hypertension, are also fueling demand. Additionally, the shift to less invasive therapies, regulatory clearances, and healthcare expenditure in emerging markets are fueling industry growth.

Based on the application:

• Coronary Artery Disease
• Peripheral Arterial Disease
• Venous Thromboembolism
• Renal Artery Disease
• Carotid Artery Disease

Coronary Artery Disease (CAD) is the most prevalent application in the PVD Diagnostics Market, following its widespread occurrence and greater demand for the early diagnosis and treatment. CAD results from the narrowing or blockage of the coronary arteries responsible for delivering blood to the heart due to plaque buildup, with potentially deadly effects such as heart attacks.

Based on the material:

• Metallic
• Biodegradable
• Polymer-based
• Nitinol-based
• Platinum-based

Metallic segment dominated the highest market share and is anticipated to maintain its dominance during the forecast period. The growth of metallic segment can be explained by the immense strength and durability of metallic materials, which are ideal for application in demanding applications like stents and grafts. Additionally, the growing incidence of peripheral artery disease and the growing adoption of minimally invasive treatments are likely to propel the growth of the Metallic segment over the next few years.

Based on the modality:

• Invasive
• Minimally invasive
• Non-invasive

Amongst these, the Minimally Invasive segment accounted for the largest market share and is expected to maintain its position in the forecast period. Growth of this segment is fueled by the increasing adoption of minimally invasive interventions, such as endovascular treatments, that are less painful, have lower recovery times, and improved patient outcomes compared to open operations. Also, the rise in the prevalence of peripheral artery disease and the expansion in minimally invasive procedures being performed for treating cardiovascular disease are driving the growth of the Minimally Invasive segment.